<DOC>
	<DOCNO>NCT02916017</DOCNO>
	<brief_summary>This study evaluate long- term safety effectiveness adalimumab participant non-infectious intermediate- , posterior- , pan-uveitis daily practice Japan .</brief_summary>
	<brief_title>HUMIRAÂ® Long-term Treatment Patients With Non-infectious Intermediate- , Posterior- , Pan-uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Panuveitis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Participants receive adalimumab treatment Noninfectious Intermediate , Posterior , Panuveitis Participants previously treat adalimumab</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Non-infectious Intermediate- , Posterior- , Pan-uveitis</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Humira</keyword>
</DOC>